Bioactive Products
| A unique collection of 51 Anti-platelet aggregation natural compounds | ||
| Catalog No: | B24 | Anti-platelet-aggregation Compound Library Screening Details |
| Size: | 1mg/well * 51 Compounds 2mg/well * 51 Compounds | |
| Cat. No. | Information |
| CFN90320 | Cinchonine Cinchonine has antiplatelet effect, mediated mainly through inhibition of Ca2+-influx and protein kinase C pathways in platelets.Dietary Cinchonine with its effects on adipogenesis and inflammation may have a potential benefit in preventing obesity. Cinchonine may be used as an anti-multidrug resistance agent. |
| CFN90321 | Cinnamic aldehyde Cinnamic aldehyde, a COX-2 inhibitor, exhibits cardioprotective, antidepressant-like, anti-leukemia, anti-oxidative and anti-inflammatory properties. Its supplementation can improve glucose and lipid homeostasis in diabetic animals. |
| CFN90330 | Dehydrocorydalin Dehydrocorydalin has anti-inflammatory,antinociceptive,antiplatelet,and anti-tumor effects and can protect the cardiovascular system. Dehydrocorydaline stimulates p38 MAPK activation, which can enhance heterodimerization of MyoD and E proteins, thus resulting in MyoD activation and myoblast differentiation. Dehydrocorydaline inhibits MCF-7 cell proliferation by inducing apoptosis mediated by regulating Bax/Bcl-2, activating caspases as well as cleaving PARP. |
| CFN97821 | Clausine D Clausine D and clausine F show significant antiplatelet aggregation activity, due to inhibition of the formation of thromboxane A2. |
| CFN90407 | Dehydrocavidine Dehydrocorydaline has antitumor activity, it inhibits MCF-7 cell proliferation by inducing apoptosis mediated by regulating Bax/Bcl-2, activating caspases as well as cleaving PARP. Dehydrocorydaline inhibits the elevation of mitochondrial membrane potential and induces ATP depletion in LPS-stimulated macrophages but neither affects basal mitochondrial membrane potential nor ATP content in non-stimulated macrophages. |
